Now showing items 1-11 of 11

    • Alcohol Intake Between Menarche and First Pregnancy: A Prospective Study of Breast Cancer Risk 

      Liu, Ying; Colditz, Graham A.; Rosner, Bernard; Berkey, Catherine S.; Collins, Laura C.; Schnitt, Stuart J.; Connolly, James L.; Chen, Wendy Y.; Willett, Walter C.; Tamimi, Rulla M. (Oxford University Press, 2013)
      Background: Adult alcohol consumption during the previous year is related to breast cancer risk. Breast tissue is particularly susceptible to carcinogens between menarche and first full-term pregnancy. No study has ...
    • Columnar Cell Lesions and Subsequent Breast Cancer Risk: A Nested Case-Control Study 

      Aroner, Sarah A.; Collins, Laura Christine; Schnitt, Stuart Jay; Connolly, James Leo; Colditz, Graham A.; Tamimi, Rulla May (BioMed Central, 2010)
      Introduction: Histologic and genetic evidence suggests that at least some columnar cell lesions (CCL) of the breast represent precursor lesions in the low-grade breast neoplasia pathway. However, the risk of subsequent ...
    • Comparison of Molecular Phenotypes of Ductal Carcinoma In Situ and Invasive Breast Cancer 

      Tamimi, Rulla May; Baer, Heather Joanne; Marotti, Jonathan; Galan, Mark; Galaburda, Laurie; Fu, Yineng; Deitz, Anne C; Connolly, James Leo; Schnitt, Stuart Jay; Colditz, Graham A.; Collins, Laura Christine (BioMed Central, 2008)
      Introduction: At least four major categories of invasive breast cancer that are associated with different clinical outcomes have been identified by gene expression profiling: luminal A, luminal B, human epidermal growth ...
    • Declining Recurrence among Ductal Carcinoma In situ Patients Treated with Breast-Conserving Surgery in the Community Setting 

      Habel, Laurel A; Achacoso, Ninah S; Haque, Reina; Geiger, Ann M; Puligandla, Balaram; Acton, Luana; Quesenberry, Charles P; Nekhlyudov, Larissa; Fletcher, Suzanne W.; Schnitt, Stuart Jay; Collins, Laura Christine (BioMed Central, 2009)
      Introduction: Randomized trials indicate that adjuvant radiotherapy plus tamoxifen decrease the five-year risk of recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery from about 20% to ...
    • Digital Quantification of Gene Expression in Sequential Breast Cancer Biopsies Reveals Activation of an Immune Response 

      Jeselsohn, Rinath M.; Werner, Lillian; Regan, Meredith M.; Fatima, Aquila; Gilmore, Lauren; Collins, Laura C.; Beck, Andrew H.; Bailey, Shannon T.; He, Housheng Hansen; Buchwalter, Gilles; Brown, Myles; Iglehart, J. Dirk; Richardson, Andrea; Come, Steven E. (Public Library of Science, 2013)
      Advancements in molecular biology have unveiled multiple breast cancer promoting pathways and potential therapeutic targets. Large randomized clinical trials remain the ultimate means of validating therapeutic efficacy, ...
    • Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype 

      Hefti, Marco M; Hu, Rong; Knoblauch, Nicholas W; Collins, Laura C; Haibe-Kains, Benjamin; Tamimi, Rulla M; Beck, Andrew H (BioMed Central, 2013)
      Introduction: Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to identify patients likely to benefit ...
    • Expression of estrogen receptor, progesterone receptor, and Ki67 in normal breast tissue in relation to subsequent risk of breast cancer 

      Oh, Hannah; Eliassen, A Heather; Wang, Molin; Smith-Warner, Stephanie A; Beck, Andrew H; Schnitt, Stuart J; Collins, Laura C; Connolly, James L; Montaser-Kouhsari, Laleh; Polyak, Kornelia; Tamimi, Rulla M (2016)
      Although expression of estrogen receptor (ER), progesterone receptor (PR), and cell proliferation marker Ki67 serve as predictive and prognostic factors in breast cancers, little is known about their roles in normal breast ...
    • Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II 

      Rice, Megan Siobhan; Tamimi, Rulla May; Connolly, James Leo; Collins, Laura Christine; Shen, Dejun; Pollak, Michael N; Rosner, Bernard Alfred; Hankinson, Susan Elizabeth; Tworoger, Shelley Slate (BioMed Central, 2012)
      Introduction: Previous research in the Nurses' Health Study (NHS) and the NHSII observed that, among women diagnosed with benign breast disease (BBD), those with predominant type 1/no type 3 lobules (a marker of complete ...
    • Luminal B Breast Tumors Are Not HER2 Positive – Authors' Response 

      Tamimi, Rulla May; Schnitt, Stuart Jay; Colditz, Graham A.; Collins, Laura Christine (BioMed Central, 2008)
    • Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers 

      Yaghjyan, Lusine; Pettersson, Andreas; Colditz, Graham A; Collins, Laura C; Schnitt, Stuart J; Beck, Andrew H; Rosner, Bernard; Vachon, Celine; Tamimi, Rulla M (Nature Publishing Group, 2015)
      Background: This study aimed to determine if associations of pre-diagnostic percent breast density, absolute dense area, and non-dense area with subsequent breast cancer risk differ by the tumour's molecular marker status. ...
    • Prevalence and Predictors of Loss of Wild Type BRCA1 in Estrogen Receptor Positive and Negative BRCA1-Associated Breast Cancers 

      Fetten, Katharina; Yassin, Yosuf; Buraimoh, Ayodele; Kim, Ji-Young; Legare, Robert D; Tung, Nadine Muskatel; Miron, Alexander; Schnitt, Stuart Jay; Gautam, Shiva Prasad; Kaplan, Jennifer; Szasz, Attila M.; Tian, Ruiyang; Wang, Zhigang C.; Collins, Laura Christine; Brock, Jane Elizabeth; Krag, Karen; Sgroi, Dennis Charles; Ryan, Paula D.; Silver, Daniel P.; Garber, Judy Ellen; Richardson, Andrea Lynn (BioMed Central, 2010)
      Introduction: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers ...